Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

Wang,Qingxue; Zhi,Zheng; Han,Hua; Zhao,Qingtao; Wang,Xing; Cao,Shumin; Zhao,Jing

doi:10.3892/ol.2022.13648

Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

Authors:
- Qingxue Wang
- Zheng Zhi
- Hua Han
- Qingtao Zhao
- Xing Wang
- Shumin Cao
- Jing Zhao
View Affiliations

Affiliations: Graduate School, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, Department of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200, P.R. China, Department of Gynecology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Department of Clinical Medical Research Center and Geriatric Key Laboratory, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China
Published online on: December 23, 2022 https://doi.org/10.3892/ol.2022.13648
Article Number: 65
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Statins are lipid‑lowering agents that have also been found to have anticancer effects. The relationship between statin use and clinical outcomes in ovarian cancer (OC) remains controversial, as previous assessments of the relationship between statin use and OC prognosis have yielded inconsistent results. Therefore, a comprehensive meta‑analysis was performed in the present study to investigate this association. Studies were systematically retrieved by searching the PubMed, Embase and Cochrane Library databases, and consulting reference lists of the related studies. The search timeframe was from database creation to September 1, 2022. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association. In the present meta‑analysis, 16 studies with 37,660 patients with OC were included, of which 11,296 patients had been prescribed statins. The results showed that statin use markedly improved the overall survival time (OS; HR, 0.79; 95% CI, 0.73‑0.85; P<0.00001) and OC‑specific survival time (HR, 0.84; 95% CI, 0.80‑0.89; P<0.00001), especially the OS time in patients with serous OC (HR, 0.81; 95% CI, 0.74‑0.89; P<0.0001) and endometrioid OC (HR, 0.80; 95% CI, 0.66‑0.98; P=0.03). In addition, survival rate was higher in patients who used statins after OC diagnosis (HR, 0.79; 95% CI, 0.73‑0.85; P<0.00001). However, there was no statistically significant association between statin use and the prognosis of mucinous and clear cell OC. The results suggested that statin use markedly improved the OS in patients with OC, including in those with serous and endometrioid OC. Statins were also found to improve the prognosis of patients of both Asian and non‑Asian ethnicities. In addition, both lipophilic and hydrophilic statins improved the survival in patients with OC, especially in patients using statins after OC diagnosis. However, the effect may vary depending on the statin type, duration of use and cancer type, and more well‑designed studies are needed to further evaluate this.

View Figures

View References

1	Momenimovahed Z, Tiznobaik A, Taheri S and Salehiniya H: Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 11:287–299. 2019. View Article : Google Scholar : PubMed/NCBI
2	Viale PH: The American cancer society's facts & figures: 2020 Edition. J Adv Pract Oncol. 11:135–136. 2020.PubMed/NCBI
3	Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
4	Delgado-Ortega L, González-Domínguez A, Borrás JM, Oliva-Moreno J, González-Haba E, Menjón S, Pérez P, Vicente D, Cordero L, Jiménez M, et al: The economic burden of disease of epithelial ovarian cancer in Spain: The OvarCost study. Eur J Health Econ. 20:135–147. 2019. View Article : Google Scholar : PubMed/NCBI
5	Orr B and Edwards RP: Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
6	Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
7	Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S and Green AC: Body size and ovarian cancer: Case-control study and systematic review (Australia). Cancer Causes Control. 12:855–863. 2001. View Article : Google Scholar : PubMed/NCBI
8	Li YC, Park MJ, Ye SK, Kim CW and Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 168:1107–1118. 1404–1405. 2006. View Article : Google Scholar : PubMed/NCBI
9	Dulak J and Józkowicz A: Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy. Curr Cancer Drug Targets. 5:579–594. 2005. View Article : Google Scholar : PubMed/NCBI
10	Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol. 23:1055–1069. 2003.PubMed/NCBI
11	Irvin S, Clarke MA, Trabert B and Wentzensen N: Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer. Cancer Causes Control. 31:869–879. 2020. View Article : Google Scholar : PubMed/NCBI
12	Lavie O, Pinchev M, Rennert HS, Segev Y and Rennert G: The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 130:615–619. 2013. View Article : Google Scholar : PubMed/NCBI
13	Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F and Webb PM: Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 43:690–709. 2007. View Article : Google Scholar : PubMed/NCBI
14	Mohammadian-Hafshejani A, Sherwin CMT and Heidari-Soureshjani S: Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. J Prev Med Hyg. 61:E331–E339. 2020.PubMed/NCBI
15	Majidi A, Na R, Dixon-Suen S, Jordan SJ and Webb PM: Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 157:678–685. 2020. View Article : Google Scholar : PubMed/NCBI
16	Li X and Zhou J: Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 84:1109–1120. 2018. View Article : Google Scholar : PubMed/NCBI
17	Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010.Available online at:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspSeptember 10–2022
18	Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
19	Irwig L, Macaskill P, Berry G and Glasziou P: Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 316:470–471. 1998.PubMed/NCBI
20	Elmore RG, Ioffe Y, Scoles DR, Karlan BY and Li AJ: Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol. 111:102–105. 2008. View Article : Google Scholar : PubMed/NCBI
21	Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Hinkula M and Läärä E: Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: A retrospective cohort study. BMC Cancer. 18:7672018. View Article : Google Scholar : PubMed/NCBI
22	Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E and Romero IL: Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: A retrospective cohort analysis. PLoS One. 9:e1045212014. View Article : Google Scholar : PubMed/NCBI
23	Vogel TJ, Goodman MT, Li AJ and Jeon CY: Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecol Oncol. 146:340–345. 2017. View Article : Google Scholar : PubMed/NCBI
24	Verdoodt F, Kjaer Hansen M, Kjaer SK, Pottegård A, Friis S and Dehlendorff C: Statin use and mortality among ovarian cancer patients: A population-based cohort study. Int J Cancer. 141:279–286. 2017. View Article : Google Scholar : PubMed/NCBI
25	Majidi A, Na R, Jordan SJ, De Fazio A and Webb PM; OPAL Study Group, : Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. Int J Cancer. 148:1608–1615. 2021. View Article : Google Scholar : PubMed/NCBI
26	Couttenier A, Lacroix O, Vaes E, Cardwell CR, De Schutter H and Robert A: Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLoS One. 12:e01892332017. View Article : Google Scholar : PubMed/NCBI
27	Bar D, Lavie O, Stein N, Feferkorn I and Shai A: The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 207:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
28	Harding BN, Delaney JA, Urban RR and Weiss NS: Use of statin medications following diagnosis in relation to survival among women with ovarian cancer. Cancer Epidemiol Biomarkers Prev. 28:1127–1133. 2019. View Article : Google Scholar : PubMed/NCBI
29	Feng JL, Dixon-Suen SC, Jordan SJ and Webb PM: Statin use and survival among women with ovarian cancer: An Australian national data-linkage study. Br J Cancer. 125:766–771. 2021. View Article : Google Scholar : PubMed/NCBI
30	Hanley GE, Kaur P, Berchuck A, Chase A, Grout B, Deurloo CM, Pike M, Richardson J, Terry KL, Webb PM and Pearce CL: Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecol Oncol. 162:461–468. 2021. View Article : Google Scholar : PubMed/NCBI
31	Kim DS, Ahn HS and Kim HJ: Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the national health insurance claims database. Int J Cancer. 150:1156–1165. 2022. View Article : Google Scholar : PubMed/NCBI
32	Chen HY, Wang Q, Xu QH, Yan L, Gao XF, Lu YH and Wang L: Statin as a combined therapy for advanced-stage ovarian cancer: A propensity score matched analysis. Biomed Res Int. 2016:91252382016. View Article : Google Scholar : PubMed/NCBI
33	Nielsen SF, Nordestgaard BG and Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med. 367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S, Liu S, et al: Statin use and all-cancer survival: Prospective results from the women's health initiative. Br J Cancer. 115:129–135. 2016. View Article : Google Scholar : PubMed/NCBI
35	Surveillance Epidemiology and End Results Program, Ovary Cancer Survival Statistics, . http://seer.cancer.gov/statfacts/html/ovary.html2021April 21–2021
36	Kwan ML, Habel LA, Flick ED, Quesenberry CP and Caan B: Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 109:573–579. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT and Lash TL: Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst. 103:1461–1468. 2011. View Article : Google Scholar : PubMed/NCBI
38	Cruz PMR, Mo H, McConathy WJ, Sabnis N and Lacko AG: The role of cholesterol metabolism and cholesterol transport in carcinogenesis: A review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol. 4:1192013. View Article : Google Scholar : PubMed/NCBI
39	Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, Zhu Y, Wang X, Zhang X and Di Y: Exogenous lipids promote the growth of breast cancer cells via CD36. Oncol Rep. 38:2105–2115. 2017. View Article : Google Scholar : PubMed/NCBI
40	Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, et al: Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 22:427–432. 2016. View Article : Google Scholar : PubMed/NCBI
41	Liu H, Liang SL, Kumar S, Weyman CM, Liu W and Zhou A: Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 63:997–1005. 2009. View Article : Google Scholar : PubMed/NCBI
42	Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU and Hilvo M: Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 119:847–854. 2018. View Article : Google Scholar : PubMed/NCBI
43	Park YH, Jung HH, Ahn JS and Im YH: Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun. 439:275–279. 2013. View Article : Google Scholar : PubMed/NCBI
44	Sassano A and Platanias LC: Statins in tumor suppression. Cancer Lett. 260:11–19. 2008. View Article : Google Scholar : PubMed/NCBI
45	Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, et al: In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 111:1562–1571. 2014. View Article : Google Scholar : PubMed/NCBI
46	Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al: Breast cancer growth prevention by statins. Cancer Res. 66:8707–8714. 2006. View Article : Google Scholar : PubMed/NCBI
47	Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 90:1774–1786. 1998. View Article : Google Scholar : PubMed/NCBI